Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Centre For Oncology And Immunology Limited currently has 1 pending office action. This 1 pending office action is assigned to 1 distinct examiner, Tiffany Nicole Grooms. As the busiest examiner, Tiffany Nicole Grooms is responsible for 1 pending office action. This single action is the only matter currently pending for the company.
The company's current prosecution is limited to 1 distinct examiner. This 1 pending office action represents the total workload the company must address. By interacting with only 1 distinct examiner, the company can focus its resources on resolving this single pending matter. The focused activity indicates that the company is currently managing only one active challenge at the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GROOMS, TIFFANY NICOLE | 1 | 57.8% | +46.3% |
| MCANANY, JOHN D | 1 | 67.2% | +43.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17735271 | COMPOSITIONS AND METHODS OF USING NMDAR INHIBITORS AND KINASE INHIBITORS TO TREAT LIVER CANCER | MCANANY, JOHN D | 12d |
| 18441806 | ENGINEERED GUIDE RNA SCAFFOLDS AND METHODS THEROF FOR ENHANCED GENOME EDITING | GROOMS, TIFFANY NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17735271 | COMPOSITIONS AND METHODS OF USING NMDAR INHIBITORS AND KINASE INHIBITORS TO TREAT LIVER CANCER | MCANANY, JOHN D | 12d |
| 18441806 | ENGINEERED GUIDE RNA SCAFFOLDS AND METHODS THEROF FOR ENHANCED GENOME EDITING | GROOMS, TIFFANY NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18441806 | ENGINEERED GUIDE RNA SCAFFOLDS AND METHODS THEROF FOR ENHANCED GENOME EDITING | GROOMS, TIFFANY NICOLE | — | §101§103§112 | Non-Final OA | — | Pending | Feb 14, 2024 |
| 17735271 | COMPOSITIONS AND METHODS OF USING NMDAR INHIBITORS AND KINASE INHIBITORS TO TREAT LIVER CANCER | MCANANY, JOHN D | 1625 | §102§103§112 | Non-Final OA | 12d | Pending | May 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial